CARsgen Therapeutics Holdings Limited (CRTHF) fair value: what the stock is really worth
We calculate from audited financials what CARsgen Therapeutics Holdings Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch CARsgen Therapeutics Holdings Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range $0.7465 – $4.80 · fair‑value band $0.1900 – $0.5400 · the $1.62 price screens above the $0.3700 fair value. Dashed = 300-day average. As of Sep 13, 2026.
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
Show more
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma. It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma, relapsed/refractory primary plasma cell leukemia, relapsed/refractory plasma cell leukemia, and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT0596, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R MM, PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence; KJ-C2527, which is in the pre-clinical stage to treat gastric cancer; CT1390B, which is in the pre-clinical stage to treat AML; and KJ-C2529, which is in the pre-clinical stage to treat B-cell malignancies. Additionally, it engages in drug research and development, manufacture and import and export handling business. The company was founded in 2014 and is headquartered in Shanghai, China.
Stock analysis
CARsgen Therapeutics Holdings Limited (CRTHF) currently trades at $1.62, while our model-based Fair Value estimate is $0.3700, implying the stock looks roughly 337.8% overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of $1.90 per share, and 2 of the 3 models we run sit above the $1.62 price.
Bear case: the Asset-Based group reads lowest at $0.9200, and 1 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1900 (bear) to $0.5400 (bull), the price of $1.62 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
CARsgen Therapeutics Holdings Limited reported revenue of 126M CNY in FY2025 versus 25.8M CNY in FY2021, a compound +48.5%/yr. Reported net income was −97.9M CNY in FY2025.
Key figures
Market cap $1.1B · P/S ratio 9.08 · EPS (TTM) $−0.0300 · Dividend yield 7.4% · Net margin −77.9% · Return on equity −11.2% · Return on assets (EBIT) −26.5% · Operating margin −116%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 117% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −77%, CRTHF screens richer than that median.
Fair Value models
Bear $0.1900Fair Value $0.3700Bull $0.5400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+218.7%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.7%
’14
’15
’16
’17
’18
’21
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,274.9% (2021) → −181.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare CARsgen Therapeutics Holdings Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Top 25%
Fair Value upside−40% · Above median
Profitability
Return on assets−10% · Below median
Net margin (TTM)−78% · Bottom 25%
Operating margin (TTM)−116% · Bottom 25%
Growth and dividend
Revenue growth126% · Top 25%
Dividend yield (TTM)7.4% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.46× · Cheaper than median
P/S (TTM)9.08× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is CARsgen Therapeutics Holdings Limited (CRTHF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.3700 versus a price of $1.62, about −77% upside (overvalued).
What is the fair value of CRTHF?
Our model-based fair value for CARsgen Therapeutics Holdings Limited is $0.3700 (as of Sep 13, 2026), built from audited fundamentals. The current price: $1.62.
What is the quality score of CRTHF?
CARsgen Therapeutics Holdings Limited has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CARsgen Therapeutics Holdings Limited (CRTHF)?
Our model-based price target is the fair value of $0.3700 (as of Sep 13, 2026) from 3 valuation models. Cautious scenario $0.1900, optimistic scenario $0.5400. It is a calculation from audited fundamentals, not an analyst target.
What is the CARsgen Therapeutics Holdings Limited stock forecast for 2026?
Our models put fair value at $0.3700, about −77% upside versus a price of $1.62 (overvalued). Cautious scenario $0.1900, optimistic scenario $0.5400. The calculation is refreshed regularly with new filings.
What is the revenue of CARsgen Therapeutics Holdings Limited (CRTHF)?
CARsgen Therapeutics Holdings Limited reported trailing-twelve-month revenue of about $126M (latest available figure, as of Sep 13, 2026).
Does CARsgen Therapeutics Holdings Limited pay a dividend?
CARsgen Therapeutics Holdings Limited currently shows a dividend yield of about 7.42% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of CARsgen Therapeutics Holdings Limited (CRTHF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CARsgen Therapeutics Holdings Limited it is $0.3700 per share (as of Sep 13, 2026), against a price of $1.62. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is CARsgen Therapeutics Holdings Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, CRTHF trades above its calculated fair value: price $1.62, fair value $0.3700, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRTHF?
No. The price is what the market pays today ($1.62); the fair value is what the company's own numbers justify ($0.3700). For CARsgen Therapeutics Holdings Limited the two are $1.25 per share apart. That gap is exactly why we show both numbers side by side.
How much is CARsgen Therapeutics Holdings Limited worth?
The market values CARsgen Therapeutics Holdings Limited at about $1.1B (market capitalisation, as of Sep 13, 2026). Per share that is $1.62; our models calculate a fair value of $0.3700 per share.
What do the bullish and bearish scenarios say about CRTHF?
Our models span a range for CARsgen Therapeutics Holdings Limited: cautious scenario $0.1900, base $0.3700, optimistic $0.5400 per share (as of Sep 13, 2026, price $1.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CARsgen Therapeutics Holdings Limited (CRTHF)?
Balance-sheet figures for CARsgen Therapeutics Holdings Limited (as of Sep 13, 2026): return on equity −11.2%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is CRTHF from its 52-week high?
CARsgen Therapeutics Holdings Limited trades at $1.62, about 26% below its 52-week high of $2.20 and 117% above the low of $0.7465 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3700 is for.
Which stocks are comparable to CARsgen Therapeutics Holdings Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CARsgen Therapeutics Holdings Limited stock attractive at the current price?
The data as of Sep 13, 2026: price $1.62, calculated fair value $0.3700 (−77%), Quality Score 60/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRTHF calculated?
We run CARsgen Therapeutics Holdings Limited through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. CARsgen Therapeutics Holdings Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with CARsgen Therapeutics Holdings Limited right now?
The price sits above even our optimistic bull case ($0.5400). The favourable scenario is already priced in. The model range is unusually wide ($0.1900 to $0.5400). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of CARsgen Therapeutics Holdings Limited
How large is the market capitalisation of CARsgen Therapeutics Holdings Limited (CRTHF)?
The market capitalisation of CARsgen Therapeutics Holdings Limited is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CARsgen Therapeutics Holdings Limited (CRTHF)?
The price-to-sales ratio of CARsgen Therapeutics Holdings Limited is 9.08 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CARsgen Therapeutics Holdings Limited (CRTHF)?
Earnings per share at CARsgen Therapeutics Holdings Limited are $−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CARsgen Therapeutics Holdings Limited (CRTHF)?
The dividend yield of CARsgen Therapeutics Holdings Limited is 7.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CARsgen Therapeutics Holdings Limited (CRTHF)?
The net margin of CARsgen Therapeutics Holdings Limited is −77.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CARsgen Therapeutics Holdings Limited (CRTHF)?
The return on equity (ROE) of CARsgen Therapeutics Holdings Limited is −11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CARsgen Therapeutics Holdings Limited (CRTHF)?
On an EBIT basis the return on assets of CARsgen Therapeutics Holdings Limited is −26.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CARsgen Therapeutics Holdings Limited (CRTHF)?
The operating margin of CARsgen Therapeutics Holdings Limited is −116% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CARsgen Therapeutics Holdings Limited (CRTHF)?
Revenue at CARsgen Therapeutics Holdings Limited is growing +126% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CARsgen Therapeutics Holdings Limited (CRTHF) generate?
The free cash flow of CARsgen Therapeutics Holdings Limited is −$243M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch CARsgen Therapeutics Holdings Limited in the live analysis
One click puts CARsgen Therapeutics Holdings Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 13, 2026